ProtoKinetix, Inc.OTC: PKTX

Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)

· Issued by ProtoKinetix, Inc.

Summary by 6ix AI

ProtoKinetix, a research-stage biotechnology company studying anti-freeze glycoproteins (proteins with sugars attached) trademarked as AAGP®, reported a net loss of $77,726 for the three months ended March 31, 2026, versus $97,690 a year earlier. It had $524 in cash at March 31, 2026 and says there is substantial doubt it can continue as a going concern.

Key details

  • At March 31, 2026, ProtoKinetix had total current assets of $1,574 and negative working capital of $235,879, compared with cash of $1,118 and negative working capital of $183,266 at December 31, 2025.
  • Research and development spending was $24,220 for the three months ended March 31, 2026, compared with $33,810 a year earlier. The company says it continues to reduce costs related to new projects and consulting fees.
  • Professional fees fell to $31,025 from $36,470 because some year-end audit and related legal fees were pushed to later periods. General and administrative costs fell to $12,660 from $14,748.
  • Net cash provided by financing activities was $26,999 for the three months ended March 31, 2026, compared with $132,000 a year earlier. The company says lower funding from private placements (sales of shares to selected investors) reflects a loss of some past investor support.
  • The company is not currently selling or marketing any products.

What’s still pending

  • The company links the going-concern doubt to its history of losses and its inability to make a profit from selling a good or service.
  • ProtoKinetix says it will need additional equity or debt financing to meet its cash flow projections, and there is no assurance it can raise enough capital.
  • The company intends to fund itself by selling common stock, and it says the price and trading volume of that stock are volatile.

6ix AI wrote this summary from the release below and checked it against the release.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless the context requires otherwise, references in this document to "ProtoKinetix", "we", "our", "us" or the "Company" are to ProtoKinetix, Incorporated.

The following discussion provides information regarding the results of operations for the three-month period ended March 31, 2026 and 2025, and our financial condition, liquidity and capital resources as of March 31, 2026 and December 31, 2025. The financial statements and the notes thereto contain detailed information that should be referred to in conjunction with this discussion.

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this Quarterly Report on Form 10-Q include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"). All statements, other than statements of historical facts, included herein and therein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward-looking statements. These forward-looking statements are identified by their use of terms and phrases such as "may," "expect," "estimate," "project," "plan," "believe," "intend," "achievable," "anticipate," "will," "continue," "potential," "should," "could," and similar terms and phrases. Although we believe that the expectations reflected in these forward-looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not considered to be) guarantees of future performance. Our results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, among others:

•Our capital requirements and the uncertainty of being able to obtain additional funding on terms acceptable to us;
•Our plans to develop and commercialize products from the AAGP® molecule;
•Ongoing testing of the AAGP® molecule;
•Our intellectual property position;
•Our commercialization, marketing and manufacturing capabilities and strategy;
•Our ability to retain key members of our senior management and key scientific consultants;
•The effects of competition;
•Our potential tax liabilities resulting from conducting business in the United States and Canada;
•The effect of further sales or issuances of our common stock and the price and volume volatility of our common stock; and
•Our common stock's limited trading history.

Finally, our future results will depend upon various other risks and uncertainties, including, but not limited to, those detailed in our filings with the SEC under the Exchange Act and the Securities Act, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the period ended March 31, 2026. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph and elsewhere in this Quarterly Report. Other than as required under securities laws, we do not assume a duty to update these forward-looking statements, whether as a result of new information, subsequent events or circumstances, changes in expectations or otherwise

Business Overview

ProtoKinetix, Incorporated is a research and development stage bio-technology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins, trademarked as AAGP®. The Company has recently been in the process of directing major efforts to the practical side of commercial validation. The commercial applications for AAGP® in large markets such as targeted health care solutions are numerous, and ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP® to market.

Results of Operations

The following table shows selected financial data and operating results for the periods noted. Following the table, please see management's discussion of significant changes.

For the Three Months Ended
March 31,
20262025
EXPENSES
Amortization$9,821$12,662
General and Administrative12,66014,748
Professional Fees31,02536,470
Research and Development24,22033,810
Net loss for the period$(77,726)(97,690)

Gross Profit and Expenses

The Company's net loss was $77,726 for the three-month period ended March 31, 2026 compared to $97,690 for the three-month period ended March 31, 2025. The expenses were primarily incurred for professional fees, consulting services related to the operations of the Company's business, research and development and other general and administrative expenses. Significant changes from the prior three-month period ended March 31, 2026 include:

General and administrative fees fell by $2,088 from $14,748 to $12,660. There are no current year marketing projects planned that will increase related expenses.

Professional fees fell by $5,445 from $36,470 to $31,025 due to some year-end audit and related legal fees pushed forward to later periods.

Research and development expenditures fell year over year with a change of $9,590 from $33,810 to $24,220 as the continues to reduce costs related to new projects and consulting fees. The company continues to pursue research partners for cost sharing and engages institutes with grants available for continued studies on our patented PKX-001 molecule.

Liquidity and Capital Resources

The following summarizes our balance sheet at March 31, 2026 and December 31, 2025:

March 31, 2026December 31, 2025
Cash$524$1,118
Working Capital$(235,879)$(183,266)

At March 31, 2026, there is a cash balance of $524 and $1,574 in total current assets and a negative working capital equity position of $235,879. Based upon our working capital equity as of March 31, 2026, we will require additional equity and/or debt financing in order to meet cash flow projections and carry forward our business objectives.

There can be no assurance that in the future we will be able to raise capital from outside sources in sufficient amounts to fund our new business. The failure to secure adequate outside funding would have an adverse effect on our plan of operation and results therefrom and a corresponding negative impact on stockholder liquidity.

Sources and Uses of Cash

Net Cash Used in Operating Activities

Net cash used in operating activities fell by $28,353 from $51,970 to $23,617 for the three-months ended March 31, 2025, and 2026, respectively. With the year over year change primarily from a change in accounts payable.

Net Cash Used in Investing Activities

Net cash used in investing activities was $3,978 for the three-month period ended March 31, 2026 while the Company had net cash used in investing activities of $25,856 for the comparative period. The difference is attributable to an decrease in patent application billings for the first quarter of the current year.

Net Cash Provided by Financing Activities

Net cash provided by financing activities fell by $105,001 from $132,000 to $26,999 for the three-months ended March 31, 2025, and 2026, respectively. The decrease of funding from private placements through the first of 2026 reflects a loss of some past investor support. We remain focused on finding financial partners for further research and development.

Going Concern

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("U.S. GAAP"), which contemplate continuation of the Company as a going concern. The history of losses and the inability for the Company to make a profit from selling a good or service has raised substantial doubt about our ability to continue as a going concern. In spite of the fact that the current cash obligations of the Company are relatively minimal, given the cash position of the Company, we have very little cash to operate. We intend to fund the Company and attempt to meet corporate obligations by selling common stock. However, the price and volume of the Company's common stock is volatile.

Off-Balance Sheet Arrangements

None.

Contractual Obligations

As a smaller reporting company, we are not required to provide the information required by paragraph (a)(5) of this Item.

Critical Accounting Policies

The preparation of financial statements in conformity with U.S. GAAP requires management to make a variety of estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and (ii) the reported amounts of revenues and expenses during the reporting periods covered by the financial statements.

Our management routinely makes judgments and estimates about the effect of matters that are inherently uncertain. As the number of variables and assumptions affecting the future resolution of the uncertainties increase, these judgments become even more subjective and complex. Although we believe that our estimates and assumptions are reasonable, actual results may differ significantly from these estimates. Changes in estimates and assumptions based upon actual results may have a material impact on our results of operation and/or financial condition. Our significant accounting policies are disclosed in Note 2 to the Financial Statements included in this Form 10-Q.

While all of the significant accounting policies are important to the Company's financial statements, the following accounting policies and the estimates derived there from have been identified as being critical.

Share-Based Compensation

The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation - Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance.

Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity's own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

Sales and Marketing

The Company is currently not selling or marketing any products.

Inflation

Although management expects that our operations will be influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the three months ended March 31, 2026.

ProtoKinetix, Inc. on 6ix

Story so far

Earlier from ProtoKinetix

All ProtoKinetix news releases